Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma

NCT04558931 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: CellProtect
DRUG: Isatuximab

Sponsor

Karolinska Institutet

Collaborators

[object Object]
[object Object]